
    
      A Phase I/II, open-label, dose escalating with 48-week treatment study to assess the safety
      and tolerability, pharmacokinetics, pharmacodynamics and efficacy of BMN 053 (previously
      known as PRO053) in subjects with Duchenne muscular dystrophy
    
  